TCM
ISEE

TCG Crossover Management’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

TCG Crossover Management’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,448,829
Closed -$96.3M – 29
2023
Q2 		$96.3M Sell
2,448,829
-2,692,289
-52% -$95M 15.8% 1
2023
Q1 		$125M Hold
5,141,118
– – 24.38% 1
2022
Q4 		$110M Buy
5,141,118
+1,263,215
+33% +$27M 19.43% 1
2022
Q3 		$69.6M Buy
3,877,903
+963,653
+33% +$12.6M 20.87% 1
2022
Q2 		$28M Buy
2,914,250
+397,330
+16% +$4.99M 11.91% 2
2022
Q1 		$42.4M Buy
2,516,920
+775,692
+45% +$11.5M 17.01% 1
2021
Q4 		$29.1M Buy
+1,741,228
New +$28.5M 13.63% 1

TCG Crossover Management's ISEE Position: Q3 2023 in Review

TCG Crossover Management sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 2,448,829 shares — an estimated $96.3M sold.

TCG Crossover Management first reported a position in ISEE in Q4 2021 and held it in 7 quarters. The position peaked at $125M in Q1 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

  • TCG Crossover Management reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • TCG Crossover Management sold 2,448,829 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $96.3M.
  • TCG Crossover Management first reported a position in IVERIC bio, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • TCG Crossover Management's IVERIC bio, Inc. Common Stock position peaked at $125M in Q1 2023.
  • 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.

Based on TCG Crossover Management's 13F filing for Q3 2023, filed 14 Nov 2023.